Pomerantz LLP is investigating Foghorn Therapeutics for potential securities fraud following the company's announcement that it will not advance its FHD-909 trial or collaboration with Lilly, and will cut its workforce by 40%. This news caused Foghorn's stock to drop 30.82% to $2.02 on October 2, 2026. The investigation focuses on whether Foghorn and its executives engaged in unlawful business practices. The firm aims to protect investors who suffered losses from the stock decline linked to these developments.
Regarding Foghorn Therapeutics Inc. as of Oct 28, 2026 03:11 WIB, here is Pluang's market snapshot for the Health sector: out of 150 priced US health stocks, 88 rose and 62 fell. Notable movers include ClearPoint Neuro Inc (CLPT) at USD 9.67 with a 6.97% increase and 100% buy order activity, Novavax Inc (NVAX) at USD 10.03 with a 6.70% rise and 74% buy order activity, and Spyre Therapeutics Inc (SYRE) at USD 98.88 with a 6.43% gain. The most notable figure is CLPT's 100% buy order activity on Pluang.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Vallourec will publish its Q3 2026 financial results on November 20, 2026, at 07:30 AM CET. The company's CEO Philippe Guillemot and CFO Nathalie Delbreuve will present the results via a conference call and webcast at 09:30 AM CET the same day. Inves...
Clearfield, Inc. announced it will release its fiscal fourth quarter 2026 earnings on November 10, 2026, after market close. The company will hold a conference call at 5:00 p.m. Eastern time to discuss the results with investors. Financial details an...
Pomerantz LLP is investigating claims against Enova International and some of its executives for potential securities fraud following Enova's withdrawal of its application to acquire Grasshopper Bancorp, which would have made it a bank holding compan...
INVO Fertility, a healthcare company specializing in fertility clinics and technologies, will implement a 1-for-4 reverse stock split effective October 30, 2026. This means every 4 shares will be consolidated into 1 share, reducing the total shares o...
